Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17β-estradiol
Authors:
- Herjan Coelingh BenninkHBHerjan Coelingh Bennink
- Agaath van BeekABAgaath van Beek
- Jürgen SponaJSJürgen Spona
- Johannes HuberJHJohannes Huber
- 1 October 1993
- journal article
- Published by Elsevier in Fertility and Sterility
- Vol. 60 (4) , 616-619
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Monitoring of hormone replacement therapyThe Lancet, 1992
- FAT‐SOLUBLE 17β‐ESTRADIOL: A WAY OF REDUCING DOSAGE IN STEROID HORMONAL SUBSTITUTION?Acta Obstetricia et Gynecologica Scandinavica, 1988
- Ovulation Inhibition with 17β‐Estradiol Cyclo‐Octyl Acetate and DesogestrelActa Obstetricia et Gynecologica Scandinavica, 1987
- Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term NORPLANT® useContraception, 1986
- Hormonal changes during the first year of use of subdermal levonoregestrel implants, NORPLANT®Contraception, 1984
- EFFECTIVITY AND ACCEPTABILITY OF ORAL CONTRACEPTIVES CONTAINING NATURAL AND ARTIFICIAL ESTROGENS IN COMBINATION WITH A GESTAGENActa Obstetricia et Gynecologica Scandinavica, 1981
- A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogensContraception, 1980